04-10-2020, 07:27 PM
rjmacs wrote:
[quote=Sarcany]
Someone did the math when that was first announced last week.
It might be useful in edge-cases, but you can't harvest enough antibodies from the survivors to make a dent in those poised to die from the virus.
Hence the rush for monoclonal antibodies.... but they still have to go through all the clinical trial other pharmaceuticals do.
That's what this guy is doing, who I posted about awhile back: http://forums.macresource.com/read.php?1...sg-2467875